Disease · MONDO_0008433
Comparisons in its trials137
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 137
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 10 MG/KG IPILIMUMAB + PLATINUM/ETOPOSIDE vs PLACEBO + PLATINUM/ETOPOSIDE: serious adverse events | 316 of 562 | 278 of 561 | 1,123 | NCT01450761 | Trial comparisons |
| Rovalpituzumab Tesirine/Dexamethasone vs Placebo: deaths from any cause | 226 of 372 | 201 of 376 | 748 | NCT03033511 | Trial comparisons |
| Rovalpituzumab Tesirine/Dexamethasone vs Placebo: serious adverse events | 157 of 368 | 87 of 373 | 741 | NCT03033511 | Trial comparisons |
| Cisplatin + Irinotecan vs Cisplatin + Etoposide: Confirmed and Unconfirmed Complete and Partial Responses. | 197 of 324 | 190 of 327 | 651 | NCT00045162 | Trial comparisons |
| Cisplatin + Irinotecan vs Cisplatin + Etoposide: serious adverse events | 107 of 321 | 31 of 327 | 648 | NCT00045162 | Trial comparisons |
| A Groups vs B Groups: Objective Response Rate | 268 of 389 | 115 of 196 | 585 | NCT04063163 | Trial comparisons |
| Group A vs Group B: deaths from any cause | 224 of 389 | 140 of 196 | 585 | NCT04063163 | Trial comparisons |
| Group A vs Group B: serious adverse events | 146 of 389 | 71 of 196 | 585 | NCT04063163 | Trial comparisons |
| Group A vs Group B: deaths from any cause | 251 of 284 | 256 of 285 | 569 | NCT02481830 | Trial comparisons |
| Group A vs Group B: serious adverse events | 183 of 282 | 171 of 265 | 547 | NCT02481830 | Trial comparisons |
| Arm I (Chemotherapy, Radiation Therapy) vs Arm II (Chemotherapy, Radiation Therapy, Atezolizumab): deaths from any cause | 120 of 270 | 132 of 274 | 544 | NCT03811002 | Trial comparisons |
| Arm I (Chemotherapy, Radiation Therapy) vs Arm II (Chemotherapy, Radiation Therapy, Atezolizumab): serious adverse events | 106 of 257 | 159 of 264 | 521 | NCT03811002 | Trial comparisons |
| Tarlatamab 1 mg to 10 mg Q2W vs Standard of Care (SOC): deaths from any cause | 111 of 254 | 152 of 255 | 509 | NCT05740566 | Trial comparisons |
| Tarlatamab 1 mg to 10 mg Q2W vs Standard of Care (SOC): serious adverse events | 129 of 252 | 125 of 244 | 496 | NCT05740566 | Trial comparisons |
| Placebo + Atezolizumab vs Tiragolumab + Atezolizumab: deaths from any cause | 171 of 247 | 180 of 243 | 490 | NCT04256421 | Trial comparisons |
| Placebo + Atezolizumab vs Tiragolumab + Atezolizumab: serious adverse events | 104 of 246 | 108 of 239 | 485 | NCT04256421 | Trial comparisons |
| Pembrolizumab/Vibostolimab vs Atezolizumab: deaths from any cause | 155 of 230 | 141 of 230 | 460 | NCT05224141 | Trial comparisons |
| Pembrolizumab/Vibostolimab vs Atezolizumab: serious adverse events | 120 of 229 | 96 of 229 | 458 | NCT05224141 | Trial comparisons |
| Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy: deaths from any cause | 175 of 227 | 196 of 230 | 457 | NCT04005716 | Trial comparisons |
| Arm A: Tislelizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy: serious adverse events | 94 of 227 | 70 of 229 | 456 | NCT04005716 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008433/comparisons